Live feed07:00:00·1012dPRReleasevia QuantisnowLarimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension TrialByQuantisnow·Wall Street's wire, on your screen.LRMR· Larimar Therapeutics Inc.Health Care
